Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma

Trial Profile

Phase I Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2019

At a glance

  • Drugs Inodiftagene-vixteplasmid (Primary) ; Inodiftagene-vixteplasmid (Primary) ; BCG; BCG
  • Indications Bladder cancer; Carcinoma
  • Focus Adverse reactions
  • Sponsors Anchiano Therapeutics; BioCancell Therapeutics
  • Most Recent Events

    • 10 Mar 2018 Status changed from recruiting to completed, according to the results presented at the 2018 Genitourinary Cancers Symposium.
    • 10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium
    • 01 Oct 2015 Results published in BioCancell media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top